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In obstetrical anesthesia — beyond the field of
general operative medicine — the effects of and
adverse reactions to an anesthetic agent must al-
ways be evaluated with reference to twoindividuals,
the mother and the infant, before a judgement
can be made about the suitability or inadequacy
of a new drug for obstetrical purposes [2, 5].
Once the pharmacological and general clinical-
anesthetic properties of the inhalation anesthetic,
Ethrane, had been extensively documented. [1,3,
8, 9, 11, 12, 13, 15, 16, 17, 19, 22, 24, 25, 26,
27] it became necessary to investigate the adequacy
or unsuitability of the drug for obstetrical pro-
cedures. In this connection it should be noted that
chemically Ethrane is similar to Methoxyflurane,
while pharmacologically it resembles Halothane
moreclosely [11].
In contrast to the numerous papers dealing with its
surgical-anesthetic properties, reports on the use
of Ethrane for obstetrical anesthesia are relatively
scarce. In addition to papers from South America,
 (
DEVOGHEL, [5] COLEMAN' [4]%and MAGNO
[21] have reported their special findings in the
obstetrical field. It thus appears that Ethrane re-
laxes the Uterus, but the effects on uterus and
fetal heart rate are promptly reversible [5].
GOLEM AN [4] and MAGNO [21] have also reported
satisfactory results with Ethrane. On our part, we
have been publishing partial results in preliminary
papers [6,7].
Our aim has been:
l.to obtain Information on the diaplacental
passage of Ethrane by measuring maternal and
neonatal Ethrane blood concentrations;
2. to evaluate postnatal adjustment of the infant
by the APGAR scoring System, acid-base balance
and blood gas analysis.
l Method
To study possible adverse effects of anesthetic
agent in the field of obstetrics, standardized an-
esthesia for primary Cesarean section appears to be
particularly suitable, since other factors that
might be mistaken for effects induced by the an-
esthetic agent are eliminated to a large extent.
Consequently, 50 healthy mothers undergoing
primary Cesarean section were given Ethrane
instead of Halothane for anesthesia. Selection of
the patients was based in part on the fact that the
fetuses showed no evidence of imminent or mani-
fest intrauterine manifestations.
After administration of Atropine (= 0.5 mg) and
pre-oxygenation in left lateral position, anesthesia
was induced with 150 to 250 mg Thiopental and
l mg/kg Succinylcholine. Under endotracheal
intubation anesthesia was maintained until delivery
of the infant, using N20/02 in a 1:1 ratio, and
Ethrane in a concentration of 1% by vol. on the
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average; Alcuronium Dichloride (Alloferin) was
given for additional muscle relaxation. Proper gas
exchange was assured by controlled hyperven-
tilation using 9 liters/minute on the average. The
maternal EGG was continuously monitored. Blood
pressure and pulse rate were checked every five
minutes. After delivery of the infant, the Ethrane
concentration was increased to 2% by vol., and the
N20/02 ratio was changed to the usual value of
2:1.
The Ethrane concentrations in the maternal blood,
äs well äs maternal blood gases and acid-base balance
were determined at the time of birth. Simultane-
ously, arterial and venous blood was cojlected
from the umbilical cord for determining Ethrane
concentrations, blood gases and acid-base balance.
\Condition of the newborn was assessed by the
APGAR scoring System. All parameters were re-
de termined 5,10 and 15 minutes after delivery.
Ethrane concentrations were determined by gas-
chromatography; blood gases and acid-base balance
were measured using the ASTRUP method and the
SIGGAARD-ANDERSON nomogram, respectively.
The newborn acid-base parameters were not cor-
rected for the individual oxygen Saturation.
2 Results
2. l Maternal parameters
From a total of 50 available protocols, 31 were
selected which provided all parameters for all
points in time.
The age of the patients averaged 25.6 years, mean
body weight was 71.3 kg. In 50% of cases the
Cesarean section involved primiparae.
Continuous ECG monitoring showed no particular
features. Following induction, blood pressure
dropped by an average of 10 to 20 mm Hg,
corresponding to a decrease of approx. 10 to 15%
from base line.
2.2 Ethrane concentrations, blood gases and acid-
base balance of mothers and infants
Of a total of 50 protocols, one was excluded for
being incomplete with reference to one reading;
thus, 49 complete protocols were available for
evaluation.
2.2.1 Ethrane concentrations in maternal and
infant blood
Ethrane concentrations in maternal arterial blood
at the time of birth averaged 6.60 mg/100 ml.
Ethrane concentrations in the umbilical artery at
this time were 3.03 mg/100 ml, those of the
umbilical vein were 3.94 mg/100 ml. Consequent-
ly, maternal Ethrane concentrations were appro-
ximately 50% higher than the umbilical venous
and more than twice äs high äs the umbilical
arterial Ethrane concentrations. The umbilical
venous exceeded the umbilical arterial Ethrane
concentrations by 0.92 mg/100 ml (Fig. 1).
Five minutes after birth, the umbilical venous
Ethrane concentrations pf the infants dropped to
0.91 mg/100 ml, 10 minutes after birth to 0.57,
and 15 minutes after birth to 0.35 mg/100 ml.
Thus, the Ethrane concentrations 15 minutes
after birth were only 1/10 those of the initial
concentrations.
If we try to correlate the maternal and the
neonatal Ethrane concentrations with reference
to the time of delivery we find merely a positive
correlation between umbilical venous and um-
bilical arterial concentrations. While other
correlations might be suspected, their statistical
significance is not distinct enough to be used with
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Fig. 1. Maternal (Ma), umbilical venous (Uv) and umbilical
arterial (Ua) Ethrane concentrations l, 5, 10 and 15 min
postpartum.
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r «0.6424 ( p « 0,001)
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Fig. 2. Correlation between umbilical venous (Uv) and
umbilical arterial Ethrane concentrations at birth.
2.2.2 Blood gases and acid-base balance of mater-
nal and infant blood
The maternal pH values at the time of birth
averaged 7.38, the umbilical venous pH was 7.28,
and the umbilical arterial pH was 7.24. The um-
bilical venous pH dropped five minutes after
birth to 7.2, and then rose to 7.24 and - 15
minutes after birth - to 7.30 (Fig. 3).
The average maternal PC02 at the time of birth
was 31.83 mm Hg, the umbilical venous PCO2
was 38.78, and the umbilical arterial PC02 was
41.87 mm HG. Five minutes after birth, the um-
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Fig. 3. Maternal (Ma), umbilical venous (Uv) and um-
bilical arterial (Ua) pH at birth äs well äs umbilical venous
(Uv) pH 5,10 and 15 min p.p.
it then dropped to 53.4 and finally to 46.4 mm Hg
(Fig. 4).
The maternal P02 at the time of birth averaged
149.3 mm Hg, the umbilical venous P02 was 36.4,
and the umbilical arterial P02 was 25.1 mm HG.
Five minutes after birth, the P(h in the umbilical
vein was 36.1, 10 minutes after birth it was 45,5
and 15 minutes after birth it was 50.6 mm Hg
(Fig. 4)
The induction-delivery-interval (IDI) averaged
17.24 minutes.
Correlating once more the various maternal and
infant parameters with reference to the time of
delivery, we obtain the following picture:
A positive correlation exists between maternal pH
on the one hand, and umbilical venous and um-
bilical arterial pH on the other hand. In addition,
we find a significant correlation between umbilical
venous and umbilical arterial pH (Figs. 5,6, 7).
A further positive correlation is obtained between
maternal PC02 on the one hand, and umbilical
venous and umbilical arterial PC02 on the other
(Figs. 8,9).
Maternal PO2 may be significantly correlated with
umbilical venous P02, while a statistically con-
spicuous relationship exists between umbilical








Fig. 4. Maternal (Ma), umbilical venous (Uv) and umbilical
arterial (Ua) PO2 and PCO2 at birth and 5,10 and 15 min
post partum.
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Fig. 7. Correlation between umbilical venous (Uv) and Fig. 10. Correlation between maternal (Ma) and umbilical
umbilical arterial (Ua) pH. venous (Uv) PO2.
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Fig. 11. Correlation between umbilical venous (Uv) and
umbilical arterial (Ua) PC>2.
Base excess or base deficit in the infant blood after
delivery shows the following picture:
From -8.05 at the time of birth, the negative base
excess improved to -7.9, -6.7, and finally to
-4.6 mEq/ liter 15 minutes after birth (Fig. 12).
Buffer base at the time of birth was 40.78, five
minutes after birth it was 43.28, 10 minutes after














Fig. 12. Umbilical venous (Uv) and umbilical arterial (Ua)
Base excess (BE), Standard-Bicarbonate (St. Bic) and
Buffer Base (BB) at birth and 5, 10 and 15 min post
partum.
Standard bicarbonate increased from 18.21 mEq/
liter at the time of birth to 18.41, 19.02, and
finally to 20.60 mEq/liter 15 minutes after birth
(Fig. 12).
3 Discussion
Major results of our investigation may be summari-
zed in various groups.
From the clinical point of view, the prospective
study of Ethrane anesthesia for Cesarean section
has given satisfactory results. Drops in blood
pressure exceeding 15% of base line readings did
not occur with cautious dosage of Ethrane; like-
wise, bradycardia, tachycardia, or disorders of
heart rhythm were not detected in the ECG
records. Similar findings are found in the literature
[e.g. l, 12,25, 26, etc.].
Mean induction-delivery-interval (IDI) was approx-
imately 17 minutes. After this time, 6.6 mg/100 ml
Ethrane were found in the maternal blood. At this
same point in time, Ethrane concentrations in the
umbilical venous blood were approximately 60%
of the maternal concentrations (3.94 mg/100 ml),
and the umbilical arterial concentrations were
46% of maternal concentrations (3.02), and 77%
of umbilical venous concentrations. In contrast to
evaluations based on a limited number of patients,
[6, 7] we have been unable to detect any statistic-
ally relevant correlation between IDI, and umbilical
venous Ethrane concentrations, äs well äs between
maternal and umbilical venous Ethrane concen-
trations. This absence of a theoretically expected
relationship may mean that the umbilical venous
concentration depends on the maternal concen-
trations only at certain points in time until delivery,
while it is determined by other criteria beyond
the seven minute ränge. If we calculate the feto-
maternal Ethrane concentration coefficient we
find that this latter — practically independently
of IDI - is situated between 0.59 and 0.63, the
shortest IDI amounting to 7 minutes. This means
that between 7 and 36 minutes, approximately
60% of the maternal Ethrane concentration
became detectable in the umbilical venous blood
of the fetuses.
There was, however, a significant correlation
between umbilical venous and umbilical arterial
J.Perinat.Med. 7(1979)
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Ethrane concentrations. The concentration ratio
rose from 0.69 to 0.77 for an IDI between 11 and
18 minutes. Subsequently, between 19 and 25
minutes, it dropped again to 0.7 and 0.68 (over
a period of 26 minutes), respectively.
These fmdings suggest that at least for IDI ex-
ceeding 7 minutes, neither IDI nor maternal con-
centrations play any significant role with reference
to the diaplacentalpassage of Ethrane. Equalization
of concentrations must have taken place already
before 7 minutes. Undoubtedly dependent on a
number of factors, the feto-maternal concentration
ratio varies between 0.33 and 0.96, with a mean
value of 0.6. This means that from 30 to 96% of
maternal Ethrane concentrations is transferred to
the fetus. The umbilical arterial/umbilical venous
'ratio averages 0.77, ranging from 0.37 to 0.99.
Just äs quickly äs diaplacental passage of Ethrane
occurs, the agent is eliminated from the body of
the infant. Postpartum concentration pätterns
show that already after five minutes 23%, after
10 minutes 14%, and after 15 minutes 9% of the
initial postpartum concentration can be detected.
The condition of the infants was assessed by the
APGAR scoring System, by the blood gas and acid-
base balance values. At the time of birth, the usual
gradients for pH, PC02 and P02 were found. These
Parameters are at least partly (blood gases) de-
pendent on the controlled Ventilation of the
mother, äs demonstrated by, among other things,
the fact that there was a highly significant re-
lationship between maternal pH and umbilical
venous pH, and also between maternal PCO2,
and umbilical venous and umbilical arterial
PC02 of the infants. The umbilical venous P02
depended directly on the maternal P02. Similarly,
there is an inverse correlation between ID-time and
umbilical venous PC02 - the longer the time until
delivery, the lower is the umbilical venous PC02.
Since simultaneously the iipibilical venous PC02,
depends directly on the maternal PC02, this corre-
lation may be best explained by the decreasing
maternal PC02 during the time until delivery.
Finally, a highly significant cörrelation was
found between umbilical venous and umbilical
arterial pH values, äs well äs between venous
P02 and arterial P02 readings. These correl-
ations are a direct or indirect consequence of
maternal-fetal and fetal-maternal gas exchan-
ges, and in this sense they should not be
directly related to the use of Ethrane. As meas-
ured by blood gases and acid-base balance, the
infants have adjusted normally during the imme-
diate postpartum phase (up to 15 minutes). The
pH increased up 7.3;rPC02 and P02 reached
approximately normal levels. The initial slight
metabolic acidosis gradually faded out in the
coürse of the observätioü period.
Summarizing,.we mäy cönclüde from our findings
that in the area of obstetrics Ethrane provides
satisfactory clinical results; that Ethrane is
rapidly transferred from mother tö fetus, in-
duction-delivery-interval and matemal concen-
trations apparently playing a significant role
only in the initial phase of Ethrane administration;
that the Ethrane concentration in the postpartum
phase decreases rapidly, since 15 minutes after
birth the Ethrane concentration in the infants
amounted only to 1/10 of the initial concentration
at the time of birth; that postpartum adjustment
of the infants äs measured by the APGAR scores,
blood gases and acid-base balance followed normal
pätterns.
These conclusions refer to the mean values äs well
äs to the individual cases. Even extreme values
ränge within tolerable limits; they belong to differ-
ent patients.
Summary
1. In a prospective study 50 patients were anesthetized
with Ethrane for Cesarean section. During anesthesia
continuous EGG monitoring showed no particular
features. Blood pressure decreased by an average 10
to 15 %of initial value.
2. Ethrane concentrations in the maternal arterial blood
were 6.6 mg/100 rnl at the time of birth, in the um-
bilical artery they averaged 3.03 mg/100 ml, in ihe
umbilical vein 3.94 mg/100 ml. In the postpartum
phase, Ethrane concentrations in the infants dropped
J.Perinat. Med. 7 (1979)
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to 0.91 mg/100 ml five minutes after birth, to 0.57
mg/100 ml 10 minutes after birth, and to 0.53 mg/
100 ml 15 minutes after birth. A positive correlation
between umbilical venous and umbilical arterial
Ethiane concentrations was found.
3. Postpartum adjustment of the infants - assessed by
the APGAR scores, blood gases and acid-base balance -
followed normal patterns. A positive correlation was
found between maternal pH on the one band, and
umbilical venous and umbilical arterial pH of the
infants on the other. In addition, there was a sig-
nificant correlation between umbilical venous and
umbilical arterial pH.
4. Maternal PCO2 correlated with the umbilical venous
and umbilical arterial PCÜ2 values. The induction-
delivery-interval showed an inverse correlation with
reference to the umbilical venous PC(>2 values.
5. Maternal PÜ2 significantly influenced the umbilical
venous PO2, and a conspicuous relationship was
found between the umbilical venous and umbilical
arterial PO2.
6. By and large, the use of Ethrane in the field of ob-
stetrical anesthesia can be called satisfactory. The
anesthetic agent is rapidly transferred from mother
to fetus, but the newborn just äs quickly eliminates
the agent if respiratory function in the postpartum
phase is adequate. Postpartum adjustment of the
infants follows normal patterns.
Keywords: Caesarean section, Ethrane, general anaesthesia, induction-delivery interval, neonatal acid base balance,
neonatal blood gases, neonatal conditions, obstetric anaesthesia.
Zusammenfassung
Klinische Untersuchungen zur Anwendung von Ethrane bei
der Sektionarkose
1. In einer prospektiven Studie wurde bei 50 Patientinnen
Ethrane zur Anästhesie bei der Sectio caesarea verwen-
det. Über den gesamten Anästhesieverlauf zeigten die
fortlaufenden EKG-Kontrollen keine Besonderheiten.
Die Blutdruckwerte fielen im Mittel um 10-15% des
Ausgangswertes ab.
2. Die Ethranekonzentrationen im mütterlichen Arterien-
blut betrugen zum Zeitpunkt der Geburt 6,6 mg/100 ml,
die Konzentrationen in der Aiteria umbilicalis lagen
im Mittel bei 3,03 mg/100 ml, die in der Vena umbili-
calis bei 3,94 mg/100 ml. In der postpartalen Phase
fielen die neonatalen Ethranekonzentrationen 5 min
nach der Geburt auf 0,91 mg/100 ml, 10 min nach der
Geburt auf 0,57 und 15 min nach der Geburt auf
0,53 mg/100 ml. Es bestand eine positive Korrelation
zwischen umbilikalvenösen und umbilikalarteriellen
Ethranekonzentrationen.
3. Die postpartale Adaptation der Neugeborenen - be-
urteilt am APGAR-Status sowie den Blutgasen und dem
Säuren-Basen-Haushalt - verlief regelrecht. Dabei
bestanden positive Korrelationnen zwischen mütter-
lichem pH einerseits sowie umbilikalvenösem und um-
bilikalarteriellem pH der Neugeborenen andererseits.
Weiterhin zeigten sich signifikante Korrelationen zwi-
schen umbilikalvenösem und umbilikalarteriellem pH.
4. Die mütterlichen PCO2-Werte korrelierten mit den
umbilikalvenösen und umbilikalarteriellen PCO2-
Werten. Die Einleitungs-Entwicklungs-Zeiten zeigten
eine inverse Korrelation zu den umbilikalvenösen
PCO2-Werten.
5. Der mütterliche PO2 beeinflußte signifikant den umbili-
kalvenösen PO2, eine auffallige Beziehung bestand zwi-
schen umbilikalvenösen und umbilikalarteriellen PO2-
Werten.
6. Insgesamt ist die Verwendung von Ethrane im Bereich
der geburtshilflichen Anästhesie zufriedenstellend. Die
Substanz wird zwar rasch von der Mutter auf den Feten
übertragen, jedoch ebenso rasch aus dem Organismus
des Neugeborenen bei adäquater postpartaler Atem-
funktion eliminiert. Die postpartale Adaptation der
Neugeborenen verläuft regelrecht.
Schlüsselwörter: Allgemeinanästhesie, Einleitungs-Entwicklungs-Zeit, Ethrane, geburtshilfliche Anästhesie, neonatale
Blutgase, neonataler Säuren-Basen-Status, Neugeborenenstatus, Sectio caesarea.
Resume
Investigations cliniques concernant l'emploi d'ethrane
pour les cesariennes
Dans une etude prospective, 50 parturientes ont ete
anesthesiees a Fethrane pour une cesarienne. Durant
Fanesthesie Fenregistrement continu d'ECG n'a
montre aucune particularite. La tension a baisse en
moyenne de 10 a 15% par rapport a la valeur initiale.
Les concentrations d'ethrane dans le sang arterielmaternel
ont ete de 6,6 mg/100 ml au moment de la naissance, de
3,03 mg/100 ml dans Pariere ombilicale et de 3,94 mg/
100 ml dans la veine ombilicale. Dans la phase post-
partale, les concentrations d'ethrane chez les bebes ont
baisse de 0,91 mg/100 ml 5 minutes apres la naissance a
0,57 mg/100 ml 10 min. apres la naissance et a 0,53 mg/
100 ml 15 min. apres la naissance. Une correlation
positive a ete observee entre les concentrations d'ethrane
dans la veine et Fartere ombilicales.
L'aju steme n t postpartum des bebes - evalue par les
scores APGAR, les gaz sanguins et Fequilibre acido-
J.Perinat. Med. 7(1979)
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basique — a suivi les normes. Une correlation positive a
ete observee entre le pH maternel d'une part et le pH de
la veine et de Tariere ombilicales des bebes d'autre part.
De plus, on a releve une correlation significative entre
le pH de la veine et de l'artere ombilicales.
II y a eu egalement correlation entre le PCO2 maternel
et les valeurs de PC(>2 de la veine et de Tariere ombilicales.
L'intervalle induction-accouchement a montre une
correlation inverse avec reference aux valeurs PCO2 de
la veine ombilicale.
Le P02 maternel a influenc?(de fa$on significative le
PO2 de la veine ombilicale et unr relation evidente a ete
observee entre le PO2 de la veine et de Tariere ombilicales.
D'une fagon generale, on peut conclure que Temploi
d'ethrane est satisfaisant en ce qui concerne Tanesthesie
obstetrique. L'agent anesthesique est rapidement trans-
fere de la mere au foetus, mais le nouveau-ne elimine
cet agent tout aussi rapidement si la fonction respiratoire
est conforme dans la phase postpartale. L'ajustement
postpartum des bebes suit les normes.
Mots-cles: Anesthesie generale, anesthesie obstetriqije, conditions, cesarienne, neonatales, equilibre acido-basique neo-
natals, ethrane, gaz sanguins neonatals, Intervalle induction-accouchement.
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